Skip to content

Innate Pharma (IPHA) Stock Soars on Positive Results From AstraZeneca’s Joint Study

Practice Stock Trading Your capital is at risk
Updated 20 Sep 2021

Innate Pharma SA (NASDAQ: IPHA) stock soared 108% higher after AstraZeneca announced a joint clinical study’s positive phase 2 clinical trial data.

new-recommended-broker-banner

AstraZeneca revealed that the study, which combined Innate Pharma’s monalizumab and AZN’s durvalumab, had positive interim results when used as a combined dosage.

The interim trial results were presented at the European Society for Medical Oncology Congress 2021 earlier today, triggering a wave of buying pressure on Innate Pharma’s stock.

The two drugs improved progression-free survival and objective response rate compared to AZN’s durvalumab alone in patients with unresectable, Stage III non-small cell lung cancer.

Monalizumab, Innate's lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumour infiltrating cytotoxic CD8+ T cells and NK cells.

Based on the positive interim results, AstraZeneca informed Innate Pharma that it plans to start a registrational study with monalizumab in combination with durvalumab in patients with unresectable Stage III non-small-cell lung cancer.

Innate  Pharma stock had given up most of its gains at writing but was still trading 43% higher and seemed likely to end the day with some of its initial gains.

Innate Pharma stock price.

Tradingview chart of Innate Pharma stock price 17-09-2021

Innate Pharma stock price was up 40% at writing but had registered gains as high as 108% to trade at $11.94.

Should You Invest in Innate Pharma Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now